Compare Davita Inc (DVA) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Ross Stores, Inc. — how do they compare? Davita Inc trades at $232 (market cap $14.92B), while Ross Stores, Inc. trades at $221 (market cap $70.87B). The key difference: Ross Stores, Inc. is far larger — about 4.8× Davita Inc's market cap, and Ross Stores, Inc. pays a 0.81% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | ROST | |
|---|---|---|
Market Cap | $14.92B | $70.87B |
Sector | Health | Consumer Cyclical |
52-Week High | $235.71 | $240.13 |
52-Week Low | $103.87 | $127.59 |
Enterprise Value | $27.47B | $71.46B |
Dividend Yield | — | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Ross Stores (ROST) trades at $219.46, down 1.53% on the day, with a bullish technical outlook supported by moving averages and consistent earnings beats. The company demonstrates strong profitability with a 9.74% net margin and 38.98% ROE, while revenue grew to $21.13B in 2025. Recent news highlights robust Q1 2026 performance with 21% sales growth and expanding margins.
The stock offers upside to the $259 consensus price target, driven by operational efficiency and store expansion. Risks include consumer spending sensitivity and competitive pressures. Analyst sentiment is strongly positive with 64% buy ratings, though valuation multiples like the 30.65 P/E warrant monitoring amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
